Willow Biosciences Inc
TSX:WLLW
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Willow Biosciences Inc
Accounts Payable
Willow Biosciences Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Willow Biosciences Inc
TSX:WLLW
|
Accounts Payable
CA$227k
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Accounts Payable
CA$1.7m
|
CAGR 3-Years
42%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Accounts Payable
$3.3m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
5%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Accounts Payable
$3.9m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
5%
|
CAGR 10-Years
12%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Accounts Payable
CA$5.5m
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Accounts Payable
$6.7m
|
CAGR 3-Years
110%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Willow Biosciences Inc
Glance View
Willow Biosciences, Inc. is a biotechnology company. The company is headquartered in Calgary, Alberta and currently employs 49 full-time employees. The company went IPO on 2017-09-14. The firm's products include tetrahydrocannabinol (THC), cannabidiol (CBD), cannabidivarin (CBDV), cannabigerovarin (CBGV), tetrahydrocannabivarin (THCV) and cannabinol (CBN). The firm has two laboratories for research and development in Mountain View, California and Burnaby, British Columbia. In addition, the Company has an analytical testing lab in Burnaby where it provides third-party analytical testing and product development services to the cannabis industry through its subsidiary Willow Analytics Inc. The company also offers testing for all forms of cannabis products, including flower, concentrates and extracted ingredients.
See Also
What is Willow Biosciences Inc's Accounts Payable?
Accounts Payable
227k
CAD
Based on the financial report for Mar 31, 2025, Willow Biosciences Inc's Accounts Payable amounts to 227k CAD.
What is Willow Biosciences Inc's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
-24%
Over the last year, the Accounts Payable growth was -52%. The average annual Accounts Payable growth rates for Willow Biosciences Inc have been -28% over the past three years , -24% over the past five years .
